AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24169031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no beauty treatments)
Number of subjects: 100
Study 24169031 — intervention group
Group type: EXPERIMENTAL
Intervention: Sense of Coherence (SOC) assessment
Number of subjects: 100
Study 24169031 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 100
Study 22161082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (n = 60)
Number of subjects: 119
Study 22161082 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control group, n = 59)
Number of subjects: 119
Study 20303051 — intervention group
Group type: EXPERIMENTAL
Intervention: Zekrya burs
Number of subjects: 40
Study 20303051 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (1.8 W, 450 mJ, 4 Hz, 113 J/cm²)
Number of subjects: 40
Study 20303051 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Nd:YAG laser irradiation (2.0 W, 100 mJ, 20 Hz, 124 J/cm²)
Number of subjects: 40
Study 20303051 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect Nd:YAG laser irradiation
Number of subjects: 40
Study 18340366 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (2 mg/kg)
Number of subjects: 60
Study 18340366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg)
Number of subjects: 60
Study 15709665 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic contour detection algorithm for indicator dilution videodensitometry
Number of subjects: 0
Study 15709665 — intervention group
Group type: COMPARATOR
Intervention: Manual contour definition
Number of subjects: 0
Study 12700955 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg once daily
Number of subjects: 133
Study 12700955 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER 2.5 mg once daily
Number of subjects: 133
Study 12700955 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER 10 mg once daily
Number of subjects: 133
Study 12700955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 10355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential neuromotor examination at 3, 6, and 12 months
Number of subjects: 157
Study 10355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential neuromotor examination at 12 months
Number of subjects: 157
Study 10355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential neuromotor examination
Number of subjects: 157
Study 10355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive neonatal urine drug screen for both cocaine and opiates
Number of subjects: 157
Study 10355807 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive maternal drug screens for concurrent cocaine and opiate use
Number of subjects: 157
Study 8918563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (starting dose 100 mg/day for 20 weeks)
Number of subjects: 19
Study 8918563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (1 g/kg body weight for 2 consecutive days every 3 weeks, repeated six times)
Number of subjects: 19
Study 1927090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cremaster muscle resection
Number of subjects: 390
Study 1927090 — intervention group
Group type: COMPARATOR
Intervention: No cremaster muscle resection
Number of subjects: 390
Study 31203776 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music and watching video games during blood draw
Number of subjects: 0
Study 31203776 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was used)
Number of subjects: 0
Study 29327055 — intervention group
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel, 125 mg/m2
Number of subjects: 695
Study 29327055 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel, 90 mg/m2
Number of subjects: 695
Study 26439786 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% body mass sled pull
Number of subjects: 22
Study 26439786 — intervention group
Group type: COMPARATOR
Intervention: 150% body mass sled pull
Number of subjects: 22
Study 26439786 — intervention group
Group type: COMPARATOR
Intervention: 75% body mass sled pull vs 150% body mass sled pull
Number of subjects: 22
Study 25265658 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day
Number of subjects: 54
Study 25265658 — intervention group
Group type: COMPARATOR
Intervention: Standard cardioprotective therapy
Number of subjects: 54
Study 22659227 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated voice reminders
Number of subjects: 598
Study 22659227 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 598
Study 19091821 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anopexy (SA)
Number of subjects: 182
Study 19091821 — intervention group
Group type: COMPARATOR
Intervention: Closed haemorrhoidectomy (CH)
Number of subjects: 182
Study 17167111 — intervention group
Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 86
Study 17167111 — intervention group
Group type: EXPERIMENTAL
Intervention: Black patients
Number of subjects: 86
Study 17167111 — intervention group
Group type: EXPERIMENTAL
Intervention: Other patients
Number of subjects: 86
Study 16304122 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 98
Study 16304122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12190621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide 3‐containing emollient (Locobase(R) Repair)
Number of subjects: 26
Study 12190621 — intervention group
Group type: COMPARATOR
Intervention: Control emollient (vaselinum album/cremor lanette ana)
Number of subjects: 26
Study 12190621 — intervention group
Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 26
Study 9618650 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 152
Study 9618650 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive use
Number of subjects: 152
Study 9618650 — intervention group
Group type: COMPARATOR
Intervention: Recent surgery
Number of subjects: 152
Study 9618650 — intervention group
Group type: COMPARATOR
Intervention: Medical induction of remission
Number of subjects: 152
Study 7631672 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing carbohydrate intolerance
Number of subjects: 3637
Study 2695862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg/die/os for 12 weeks)
Number of subjects: 60
Study 2695862 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent to pirenzepine for 12 weeks)
Number of subjects: 60
Study 606771 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemically disrupted influenza A/New Jersey/76 virus vaccine
Number of subjects: 112
Study 606771 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐virus influenza A/New Jersey/76 virus vaccine
Number of subjects: 112
Study 606771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation from Wyeth Laboratories
Number of subjects: 112
Study 606771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation from Parke, Davis and Company
Number of subjects: 112
Study 606771 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation from Merrell‐National Laboratories
Number of subjects: 112
Study 31117116 — intervention group
Group type: EXPERIMENTAL
Intervention: National strategy to reduce foodborne Campylobacter infection
Number of subjects: 39970
Study 31117116 — intervention group
Group type: COMPARATOR
Intervention: Pre-2006 notification rates
Number of subjects: 39970
Study 31117116 — intervention group
Group type: COMPARATOR
Intervention: Hospitalization rates pre-2006
Number of subjects: 39970
Study 31117116 — intervention group
Group type: COMPARATOR
Intervention: Post-2008 age-standardized incidence rates
Number of subjects: 39970
Study 27291563 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair basketball players
Number of subjects: 196
Study 25994233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model and reading materials on epitympanic anatomy
Number of subjects: 72
Study 25994233 — intervention group
Group type: COMPARATOR
Intervention: 2D group (reading material and pictures)
Number of subjects: 72
Study 25994233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D group (3D model and reading materials)
Number of subjects: 72
Study 22773302 — intervention group
Group type: EXPERIMENTAL
Intervention: General combined epidural anesthesia (Group B)
Number of subjects: 40
Study 22773302 — intervention group
Group type: COMPARATOR
Intervention: Routine general anesthesia (Group A)
Number of subjects: 40
Study 20127139 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD6244 (100 mg twice daily)
Number of subjects: 69
Study 20127139 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1,250 mg/m2 twice daily for 2 weeks followed by 1-week rest)
Number of subjects: 69
Study 19169187 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200-400 mg/day
Number of subjects: 174
Study 19169187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 17113759 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride (200-600 mg/day)
Number of subjects: 85
Study 17113759 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (5-15 mg/day)
Number of subjects: 85
Study 14729297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (three patient-focused interventions)
Number of subjects: 0
Study 14729297 — intervention group
Group type: COMPARATOR
Intervention: Control group (attention control and control group)
Number of subjects: 0
Study 11584990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 0
Study 11584990 — intervention group
Group type: COMPARATOR
Intervention: TMP-SMX (Trimethoprim-Sulfamethoxazole)
Number of subjects: 0
Study 9389397 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (150 microg subcutaneously every 8 hours through postoperative day 5)
Number of subjects: 120
Study 9389397 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment after pancreaticoduodenectomy)
Number of subjects: 120
Study 9389397 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 120
Study 9389397 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 9389397 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperative pancreaticoduodenectomy
Number of subjects: 120
Study 9389397 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation
Number of subjects: 120
Study 8187320 — intervention group
Group type: EXPERIMENTAL
Intervention: 96-hour fast with water freely available
Number of subjects: 6
Study 8187320 — intervention group
Group type: COMPARATOR
Intervention: Normal hospital diet
Number of subjects: 6
Study 3360052 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 200 mg i.v.
Number of subjects: 6
Study 3360052 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 400 mg p.o.
Number of subjects: 6
Study 31969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) 10 mg/kg plus pyridoxine for 12 months
Number of subjects: 300
Study 31969368 — intervention group
Group type: COMPARATOR
Intervention: No INH (Control)
Number of subjects: 300
Study 31969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 300
Study 31969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined outcome of TB infection, disease and mortality
Number of subjects: 300
Study 31969368 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses excluding infants with baseline TB-specific responses on flow cytometry
Number of subjects: 300
Study 31626078 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intervention
Number of subjects: 100
Study 31626078 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 28610590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) intervention with 2-week training in WHO Community Case Management followed by 12 months of CQI mentoring.
Number of subjects: 606
Study 28610590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CQI intervention).
Number of subjects: 606
Study 25223966 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided nerve block
Number of subjects: 400
Study 25223966 — intervention group
Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 400
Study 25223966 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 400
Study 23500314 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning (RIPC) by cycles of inflation and deflation of the stent balloon during PCI
Number of subjects: 225
Study 23500314 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 225
Study 23500314 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic post-conditioning (RIPC)
Number of subjects: 225
Study 22038744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 2127
Study 22038744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2127
Study 16412796 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen therapy (O-ET, 2 mg oral micronized 17beta estradiol daily)
Number of subjects: 20
Study 16412796 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (T-ET, 17beta estradiol 1.5 mg gel daily)
Number of subjects: 20
Study 15256300 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (individual treatment session, two follow-up calls, information booklet)
Number of subjects: 69
Study 15256300 — intervention group
Group type: COMPARATOR
Intervention: Standardised fact-sheet about infectious mononucleosis (control group)
Number of subjects: 69
Study 11748518 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (once-daily oral for at least 2 weeks)
Number of subjects: 34
Study 11748518 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving diltiazem)
Number of subjects: 34
Study 9286886 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 150
Study 9286886 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate
Number of subjects: 150
Study 9286886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 150
Study 8379636 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving (larger glove on the outside)
Number of subjects: 17
Study 8379636 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving (larger glove on the inside)
Number of subjects: 17
Study 8379636 — intervention group
Group type: COMPARATOR
Intervention: Single gloving
Number of subjects: 17
Study 8379636 — intervention group
Group type: EXPERIMENTAL
Intervention: Double gloving (smaller glove on the outside)
Number of subjects: 17
Study 3530302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg triazolam
Number of subjects: 12
Study 3530302 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mg triazolam
Number of subjects: 12
Study 3530302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29351490 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Caloric Restriction (CR) for 24 months (n = 34)
Number of subjects: 53
Study 29351490 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum diet (AL) for 24 months (n = 19)
Number of subjects: 53
Study 26268138 — intervention group
Group type: EXPERIMENTAL
Intervention: RP‐1127 (glyburide for injection)
Number of subjects: 100
Study 26268138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25309754 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 111
Study 25309754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behaviour
Number of subjects: 111
Study 22773022 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 90
Study 22773022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 22773022 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 90
Study 20613611 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporalis muscle and facial flap
Number of subjects: 20
Study 20613611 — intervention group
Group type: COMPARATOR
Intervention: Dermal graft
Number of subjects: 20
Study 18076222 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training, 3 times per week for 8 weeks before ballet practice
Number of subjects: 22
Study 18076222 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 22
Study 18076222 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 22
Study 16200849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 U/kg insulin (group A)
Number of subjects: 55
Study 16200849 — intervention group
Group type: COMPARATOR
Intervention: 0.1 U/kg insulin (group B)
Number of subjects: 55
Study 16200849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 U/kg insulin and 0.1 U/kg insulin
Number of subjects: 55
Study 12145076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand (Trachlight)
Number of subjects: 60
Study 12145076 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laryngoscope (Macintosh blade)
Number of subjects: 60
Study 12145076 — intervention group
Group type: COMPARATOR
Intervention: Laryngoscopy alone
Number of subjects: 60
Study 10664918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 75
Study 10664918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8737030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (daytime glibenclamide and evening NPH insulin)
Number of subjects: 39
Study 8737030 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin treatment (rapid acting insulin before meals and NPH insulin at bedtime)
Number of subjects: 39
Study 1433619 — intervention group
Group type: COMPARATOR
Intervention: Acute bolus intrathecal baclofen
Number of subjects: 10
Study 1433619 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic continuous intrathecal baclofen
Number of subjects: 10
Study 3904543 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline loading dose
Number of subjects: 19
Study 3904543 — intervention group
Group type: COMPARATOR
Intervention: Oral aminophylline loading dose
Number of subjects: 19
Study 30541073 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer education techniques (symposium attendance or reading printed handouts)
Number of subjects: 432
Study 29448917 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone
Number of subjects: 121
Study 29448917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 121
Study 27542666 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered label (PCL) strategy
Number of subjects: 845
Study 24885674 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multidisciplinary care pathway
Number of subjects: 256
Study 24885674 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 256
Study 22230057 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom PRK
Number of subjects: 40
Study 22230057 — intervention group
Group type: COMPARATOR
Intervention: Conventional PRK
Number of subjects: 40
Study 20142784 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger power training (SP)
Number of subjects: 32
Study 20142784 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaker power training (WP)
Number of subjects: 32
Study 20142784 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaker strength training (WS)
Number of subjects: 32
Study 20142784 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 32
Study 18513639 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson
Number of subjects: 48
Study 18513639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15483562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (0.038 mg/kg)
Number of subjects: 30
Study 15483562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12521654 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg ethinylestradiol + 2 mg dienogest (30EE/DNG)
Number of subjects: 100
Study 12521654 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 2 mg dienogest (20EE/DNG)
Number of subjects: 100
Study 12521654 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg ethinylestradiol + 2 mg estradiol valerate + 2 mg dienogest (EE/EV/DNG)
Number of subjects: 100
Study 12521654 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol + 100 microg levonorgestrel (EE/LNG)
Number of subjects: 100
Study 10567752 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection
Number of subjects: 10
Study 8733685 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT
Number of subjects: 26
Study 30770536 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy during rehabilitation
Number of subjects: 32
Study 30770536 — intervention group
Group type: COMPARATOR
Intervention: No music during rehabilitation (Control)
Number of subjects: 32
Study 28451784 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent program (Stand Up Victoria) with individual-, organisational-, and environmental-level change strategies; sit-stand workstations
Number of subjects: 231
Study 28451784 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 231
Study 27682068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Fusidic Acid (FA) in combination with Oral Rifampin (RIF)
Number of subjects: 14
Study 27682068 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-Care (SOC) intravenous antibiotics
Number of subjects: 14
Study 24748637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D2 50,000 IU monthly for 24 weeks (Ca+D)
Number of subjects: 72
Study 24748637 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate as limestone (approximately 938 mg elemental calcium twice daily) alone (Ca)
Number of subjects: 72
Study 24748637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca+D
Number of subjects: 72